A method for coupling antibodies with acridinium ester and its application
By optimizing the reaction with disodium EDTA before antibody conjugation with acridine ester, the false positive problem in acridine ester marker detection was solved, achieving higher detection specificity and accuracy.
Patent Information
- Application Number
- CN202011587511.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-12-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-12-29
Smart Images

Figure CN114689835B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunoassay, and in particular to a method for coupling an acridinium ester to an antibody and an application thereof. Background Art
[0002] Chemiluminescence immunoassay (CLIA) is a technique that combines highly sensitive chemiluminescence assay technology with highly specific immune reactions and is used for the detection and analysis of various antigens or antibodies. It is the latest immunoassay technology developed after radioimmunoassay, enzyme immunoassay, fluorescence immunoassay and time-resolved fluorescence immunoassay.
[0003] Acridinium esters are a class of chemical substances that can be used as chemiluminescent markers. Under alkaline conditions, acridinium ester molecules can be attacked by hydrogen peroxide to generate ethylene dioxide. Ethylene dioxide is unstable and decomposes into CO2 and electronically excited N-methylacridone. When it returns to the ground state, it emits photons with a wavelength of 430nm.
[0004] Acridinium ester labels have special groups that produce light in their chemical structure and directly participate in the luminescent reaction during luminescent immunoassay. Usually, this type of substance has no background luminescence and can be used to detect samples with low or trace concentrations in the reaction. It is a type of luminescent agent with high luminescence efficiency. However, acridinium ester-labeled chemiluminescent detection often results in false positive results, and the specificity of the detection needs to be improved.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The object of the present invention is to provide a method for coupling an acridinium ester to an antibody and its application.
[0007] The present invention is achieved in that:
[0008] In a first aspect, an embodiment of the present invention provides a method for coupling an antibody with an acridinium ester, comprising: before coupling the antibody with an acridinium ester, mixing the antibody with disodium EDTA for reaction.
[0009] In a second aspect, an embodiment of the present invention provides the use of disodium EDTA in the preparation of a reagent for improving the detection specificity of acridinium ester-labeled chemiluminescent immunoassay.
[0010] The present invention can improve the reactivity of antibody-acridinium ester coupling, and this improvement is not limited to specific antibody types, and has an effect on antibodies against different antigens. The region with the biggest difference between different antibodies is CDR, but the coupling with aridinium ester is at the Fc end of the antibody. The inventors have verified that the present invention is effective in multiple projects, and the following is only an example.
[0011] The present invention has the following beneficial effects:
[0012] The invention provides a method for coupling an antibody with an acridinium ester and an application thereof. The method comprises the following steps: firstly mixing disodium EDTA with an antibody for reaction, and then coupling the antibody after the mixed reaction with an acridinium ester. Compared with the prior art, the antibody treated with disodium EDTA is coupled with an acridinium ester and then detected, which can effectively avoid or reduce the false positive phenomenon in chemiluminescent immunoassay and improve the specificity of the detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0014] Figure 1 The linearity test result of the calibration product in Experimental Example 1 of the present invention;
[0015] Figure 2 This is the linearity test result of the calibration product in Experimental Example 2 of the present invention. DETAILED DESCRIPTION
[0016] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0017] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0018] Definition
[0019] The "coupling" mentioned in this article can refer to the process of obtaining an organic molecule by a certain chemical reaction between two organic chemical units, which can also be called combination.
[0020] The "chemiluminescent immunoassay" described in this article is an immunoassay technology that combines the specific reaction of antigen and antibody with the sensitive chemiluminescent reaction. From the reaction principle, chemiluminescent immunoassay technology is mainly divided into direct chemiluminescence and enzymatic chemiluminescence. In direct chemiluminescence, the chemiluminescent agent directly participates in the luminescent reaction without the catalysis of the enzyme during the luminescent immunoassay process. They have a unique group that produces luminescence in the chemical structure and can directly label the antigen or antibody. Representative luminescent agents include acridinium esters.
[0021] The "acridinium ester" described in this article is a tricyclic organic compound. When oxidized by H2O2 under alkaline conditions, it emits light with a wavelength of 470nm and has a very high luminescence efficiency. Its excited state product N-methylacridone is the luminophore of the luminescence reaction system.
[0022] The embodiment of the present invention provides a method for coupling an antibody with an acridinium ester, which comprises: before coupling the antibody with the acridinium ester, mixing the antibody with disodium EDTA for reaction.
[0023] The inventors discovered through a series of creative work that pre-treating the antibody with disodium EDTA before mixing and coupling the antibody with acridinium ester and then detecting the pre-treated antibody and acridinium ester conjugate can effectively avoid or reduce the false positive phenomenon in chemiluminescent immunoassay and effectively improve the specificity of the detection.
[0024] In some embodiments, the working concentration of disodium EDTA when mixed with the antibody is 1 to 10 mM. Specifically, the working concentration of disodium EDTA can be any concentration of 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, and 10 mM.
[0025] Preferably, the working concentration of disodium EDTA when mixed with the antibody is 2 to 5 mM. When disodium EDTA is within this concentration range, the specificity of the detection can be more effectively reduced or avoided.
[0026] Preferably, the mixing time of disodium EDTA and the antibody is 5 to 40 minutes. In some embodiments, the mixing time of disodium EDTA and the antibody can be any time among 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes and 40 minutes.
[0027] Preferably, the mixing temperature of disodium EDTA and the antibody is 15-25° C. In some embodiments, the mixing temperature can be any temperature of 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., and 25° C.
[0028] Preferably, when disodium EDTA is mixed with the antibody, the concentration of the antibody solution is 1 to 3 mg / mL. In some embodiments, the concentration of the antibody solution can be any of 1 mg / mL, 1.5 mg / mL, 2 mg / mL, 2.5 mg / mL, and 3 mg / mL.
[0029] In some embodiments, the acridinium ester and antibody solution are mixed in a manner that: after mixing, they are reacted at room temperature in the dark. Specifically, they can be mixed by vortexing immediately in a small vortex shaker for 10 seconds; after a short centrifugation in a small centrifuge, they are reacted at room temperature in the dark for 40 to 80 minutes, and then blocked with a glycine solution.
[0030] In some embodiments, after the acridinium ester is mixed and coupled with the antibody, the method further comprises a purification step for the mixture or the conjugate.
[0031] Preferably, the purification step comprises: adding the coupled conjugate to a 0.5 ml 7k desalting column, centrifuging at 1500 xg for 2 min in a high-speed centrifuge, collecting the desalted marker, fixing the desalted and purified conjugate to a certain concentration using PBS (20 mM PB and 150 mM Nacl, PH 7.4) solution, adding an equal volume of high-pressure glycerol to mix, and storing at -20°C.
[0032] The present invention does not specifically limit the antibody, and can be selected from any antibody type that can be labeled with an acridinium ester. It can be one or both of a genetically engineered antibody, a polyclonal antibody, and a monoclonal antibody. According to the source classification, it can be one or more of a mouse antibody, a rabbit antibody, a sheep antibody, and an alpaca antibody.
[0033] When the antibody is coupled to acridinium ester, the concentration of the acridinium ester solution is 0.05-2 mM, and can be any concentration among 0.05 mM, 0.10 mM, 0.15 mM, and 0.2 mM; the amount of the antibody added is 50-1000 μg, and can be any value among 50 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg, 900 μg, and 1000 μg.
[0034] Preferably, the conditions for coupling the antibody to the acridinium ester are: mixing in the dark for 10 to 60 minutes at 15 to 25° C., adding the bovine serum albumin BSA solution, and mixing in the dark for 10 to 60 minutes. The mixing method for mixing in the dark is preferably oscillation, and the time can be any time of 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, and 60 minutes.
[0035] Preferably, when the antibody is coupled to acridinium ester, the coupling buffer used is carbonate CBS buffer;
[0036] Preferably, the CBS buffer comprises: 15-20 mM CB and 130-170 mM NaCl, pH 9-10.
[0037] In addition, the embodiment of the present invention also provides the use of disodium EDTA in the preparation of a reagent for improving the detection specificity of acridinium ester-labeled chemiluminescent immunoassay.
[0038] Unless otherwise specified, the chemical reagents used in the examples of the present invention were all analytically pure and purchased from Sigma-Aldrich. The chemiluminescence detector used was Hamamatsu BHP9507 chemiluminescence detector produced by Hamamatsu Photonics Technology Co., Ltd., Beijing, China.
[0039] Example 1
[0040] A method for coupling an antibody with an acridinium ester, comprising the following steps:
[0041] (1) Antibody treatment:
[0042] Take a certain amount of the antibody to be labeled, and purify it into carbonate CBS (20mM CB and 150mM NaCl pH9.5) buffer solution by desalting displacement. Divide the purified antibody into two parts, add disodium EDTA to one of the antibody solutions, and use CBS solution to adjust the antibody concentration to 2mg / mL. The working concentration of disodium EDTA is 5mM. After the antibody and disodium EDTA are fully mixed, react at room temperature for half an hour; the other antibody solution is directly adjusted to the same concentration of 2mg / ml using CBS solution for standby use.
[0043] (2) Antibody conjugation with acridinium ester:
[0044] 2.1. Measure 12 mL CBS (20 mM CB and 150 mM NaCl pH 9.5) buffer solution into a centrifuge tube;
[0045] 2.2. Add 1 mg of the antibody to be labeled and mix thoroughly;
[0046] 2.3. Add 400 μL of acridinium ester solution (1 mg / mL), mix thoroughly, and shake at room temperature in the dark for 1 hour;
[0047] 2.4. Add 1.4 mL of 10% BSA solution, mix well, and shake at room temperature in the dark for 30 minutes;
[0048] 2.5. Add the above product to a 30 mL G25 desalting column and centrifuge at 1500 xg for 2 min in a high-speed centrifuge to collect the desalted marker. Use PBS (20 mM PB and 150 mM NaCl, pH 7.4) solution to adjust the desalted and purified conjugate to a certain concentration, add an equal volume of glycerol to mix, and store at -20°C.
[0049] Example 2
[0050] A method for coupling an acridinium ester to an antibody is substantially the same as in Example 1, except that the working concentration of disodium EDTA is different, as follows:
[0051] The working concentration of disodium EDTA is 4 mM.
[0052] Example 3
[0053] A method for coupling an acridinium ester to an antibody is substantially the same as in Example 1, except that the working concentration of disodium EDTA is different, as follows:
[0054] The working concentration of disodium EDTA is 3 mM.
[0055] Example 4
[0056] A method for coupling an acridinium ester to an antibody is substantially the same as in Example 1, except that the working concentration of disodium EDTA is different, as follows:
[0057] The working concentration of disodium EDTA is 2 mM.
[0058] Example 5
[0059] A method for coupling an acridinium ester to an antibody is substantially the same as in Example 1, except that the working concentration of disodium EDTA is different, as follows:
[0060] The working concentration of disodium EDTA is 1 mM.
[0061] Example 6
[0062] A method for coupling an acridinium ester to an antibody is substantially the same as in Example 1, except that the working concentration of disodium EDTA is different, as follows:
[0063] The working concentration of disodium EDTA is 8 mM.
[0064] Example 7
[0065] A method for coupling an acridinium ester to an antibody is substantially the same as in Example 1, except that the working concentration of disodium EDTA is different, as follows:
[0066] The working concentration of disodium EDTA is 10 mM.
[0067] Comparative Example 1
[0068] A method for coupling an antibody with an acridinium ester is substantially the same as that of Example 1, except that disodium EDTA is not added.
[0069] Comparative Example 2
[0070] A method for coupling an acridinium ester to an antibody is substantially the same as Example 1, except that the timing of adding disodium EDTA is different. In this comparative example, disodium EDTA is added as a buffer after the acridinium ester and the antibody are mixed.
[0071] It should be noted that, in this comparative example 1, the working concentration of disodium EDTA is 5 mM.
[0072] Test Example 1
[0073] Experimental methods
[0074] The acridinium ester antibody coupling methods provided in Example 1 and Comparative Example 1 were respectively used to couple CA153 antibody (antibody to be labeled) and acridinium ester solution, and the coupled antibodies were used to detect calibrators and clinical samples.
[0075] The test results of the calibration materials are shown in Table 1.
[0076] Table 1 Calibrator test results
[0077]
[0078] From Table 1 and Figure 1 It can be seen that using disodium EDTA to pretreat the antibody can obtain a better linear value R 2 =0.99, and the upper limit of the linear range of the calibrator can reach 1000U / mL.
[0079] The test results of clinical samples are shown in Table 2.
[0080] Table 2 Clinical sample test results
[0081] Clinical samples (U / mL) Example 1 (U / mL) Comparative Example 1 (U / mL) Sample 1: 19.6 20.118 100.1669 Sample 2: 22.7 21.2277 40.0903 Sample 3: 24.8 23.1523 28.6699 Sample 4: 26.8 27.1016 28.6209 Sample 5: 85.4 84.4134 79.5694 Sample 6: 137.9 132.0966 153.8142
[0082] As shown in Table 2, pretreatment of the antibody with disodium EDTA can improve the accuracy of detection and reduce the influence of the antiserum matrix. Comparative Example 1 detected false positive results in both clinical samples 1 and 2, while the values detected by the method of the present invention were consistent with the clinical values.
[0083] Test Example 2
[0084] Experimental methods
[0085] The acridinium ester antibody coupling methods provided in Example 1 and Comparative Example 2 were respectively used to couple CA153 antibody and acridinium ester solution, and the coupled antibodies were used to detect calibrators and clinical samples.
[0086] The test results of the calibration materials are shown in Table 3.
[0087] Table 3 Test results of calibrators
[0088]
[0089] From Table 3 and Figure 2 It can be seen that using disodium EDTA to pretreat the antibody can obtain a better linear value R 2 =0.99, and the upper limit of the linear range of the calibrator can reach 1000U / mL. Adding disodium EDTA to the dilution after labeling does not improve the linearity and detection range of the test.
[0090] The test results of clinical samples are shown in Table 4.
[0091] Table 4 Clinical sample test results
[0092] Clinical samples (U / mL) Example 1 (U / mL) Comparative Example 1 (U / mL) Sample 1: 19.6 20.118 130.1576 Sample 2: 22.7 21.2277 58.1648
[0093] The results show that adding disodium EDTA after labeling does not improve the detection of false positive samples in Test Example 1.
[0094] Test Example 3
[0095] Experimental methods
[0096] The CA153 antibody and the acridinium ester solution were coupled using the acridinium ester antibody coupling methods provided in Examples 1 to 7, and the coupled antibodies were used to detect the calibrators and clinical samples.
[0097] Please refer to Table 5 for the test results.
[0098] Table 5 Test results
[0099] Sample 1 (U / mL) Sample 2 (U / mL) Example 1 20.118 21.2277 Example 2 19.684 22.613 Example 3 20.038 22.164 Example 4 18.217 22.717 Example 5 17.846 20.163 Example 6 21.012 24.384 Example 7 21.274 24.891
[0100] As can be seen from the results, in Examples 1-7, CA153 antibodies were pretreated with 1-10 mM disodium EDTA at different concentrations and then coupled with acridinium esters for labeling. The above-mentioned clinical samples 1 and 2 that are easily detected as false positives were tested. After being pretreated with 1-10 mM disodium EDTA before antibody coupling labeling, the test values were consistent with the actual clinical values and no false positive results were displayed. In particular, the example pretreated with 2-5 mM disodium EDTA had a deviation of no more than 5% from the clinical value.
[0101] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for coupling an antibody with an acridinium ester, characterized in that: It includes: Before the antibody is coupled to the acridinium ester, the antibody is mixed with disodium EDTA for reaction; the working concentration of disodium EDTA and the antibody is 1-10 mM; The mixed reaction time of disodium EDTA and antibody is 5 to 40 minutes.
2. The method for coupling an acridinium ester to an antibody according to claim 1, wherein: The working concentration of disodium EDTA when mixed with antibodies is 2-5 mM.
3. The method for coupling an acridinium ester to an antibody according to claim 1, characterized in that: When disodium EDTA is mixed with the antibody, the concentration of the antibody solution is 1 to 3 mg / mL.
4. The method for coupling an acridinium ester to an antibody according to claim 3, characterized in that: The antibody is any one or more of a genetically engineered antibody, a monoclonal antibody, a polyclonal antibody or an antibody fragment.
5. The method for coupling an acridinium ester to an antibody according to any one of claims 1 to 3, characterized in that: When the antibody is coupled to acridinium ester, the concentration of the acridinium ester solution is 0.05-2 mM, and the amount of the antibody added is 50-1000 μg.
6. The method for coupling an acridinium ester to an antibody according to claim 5, characterized in that: The conditions for coupling the antibody to the acridinium ester are: mixing for 10 to 60 minutes at 15 to 25° C. in the dark, adding the bovine serum albumin BSA solution, and mixing for 10 to 60 minutes in the dark.
7. The method for coupling an acridinium ester to an antibody according to claim 5, characterized in that: When the antibody was coupled to acridinium ester, the coupling buffer used was carbonate CBS buffer.
8. The method for conjugating an antibody to an acridinium ester according to claim 7, characterized in that: The CBS buffer comprises: 15-20 mM CB and 130-170 mM NaCl, pH 9-10.
9. Use of disodium EDTA in the preparation of a reagent for improving the detection specificity of acridinium ester-labeled chemiluminescent immunoassay, characterized in that: Before the antibody is coupled to the acridinium ester, the antibody is mixed with disodium EDTA for reaction; the working concentration of disodium EDTA and the antibody when mixed is 1 to 10 mM; and the mixing reaction time of disodium EDTA and the antibody is 5 to 40 minutes.
